Literature DB >> 1435076

Pulmonary biotransformation of insulin in rat and rabbit.

F Y Liu1, D O Kildsig, A K Mitra.   

Abstract

In vitro biodegradation of insulin in rabbit and rat lung homogenates was investigated. Insulin can be sequentially metabolized into two primary fragments in rabbit lung homogenate by an aminopeptidase. The amino acid sequences of the fragments were found to be the des-Phe-InsulinB1 (Metabolite I) and des-Phe-Val-InsulinB1-2 (Metabolite II). However, only the former metabolite (Metabolite I) was identified in the rat lung homogenate. The km and Vm values associated with rabbit lung homogenate were 0.29 +/- 0.14 mM and 16.4 +/- 6.9 microM/hr/mg protein, respectively, whereas those for a rabbit lung preparation containing both microsomes and cytosol were 0.22 +/- 0.07 mM and 17.9 +/- 5.4 microM/hr/mg protein, respectively. The km and Vm associated with the cytosolic fraction of rabbit lung were 0.32 +/- 0.16 and 20.6 +/- 6.1 microM/hr/mg protein, respectively. The results indicate that the lung aminopeptidase may be a cytosolic enzyme. The degradation of dimeric insulin in the lung homogenate was faster than that of hexameric insulin due to the difference in collision frequency between the enzyme and insulin aggregates. The major metabolites in the lungs reportedly retain almost the same bioactivity of insulin, suggesting that the pulmonary route of insulin delivery will not adversely affect its hypoglycemic activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1435076     DOI: 10.1016/0024-3205(92)90313-e

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Pulmonary delivery of free and liposomal insulin.

Authors:  F Y Liu; Z Shao; D O Kildsig; A K Mitra
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

2.  Study on pulmonary delivery of salmon calcitonin in rats: effects of protease inhibitors and absorption enhancers.

Authors:  S Kobayashi; S Kondo; K Juni
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

3.  Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats.

Authors:  Mathangi Gopalakrishnan; Sandra Suarez; Anthony J Hickey; Jogarao V S Gobburu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

4.  Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats.

Authors:  S Suarez; L Garcia-Contreras; D Sarubbi; E Flanders; D O'Toole; J Smart; A J Hickey
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

Review 5.  Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics.

Authors:  Masahiro Sakagami
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  In situ ileal absorption of insulin in rats: effects of hyaluronidase pretreatment diminishing the mucous/glycocalyx layers.

Authors:  Mariko Morishita; Yoshinobu Aoki; Masahiro Sakagami; Tsuneji Nagai; Kozo Takayama
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

Review 7.  A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.

Authors:  Nishat Fatima; Vichitra Kaushik; Amjad Ayoub
Journal:  Iran J Med Sci       Date:  2021-05

Review 8.  The lung as a route for systemic delivery of therapeutic proteins and peptides.

Authors:  R U Agu; M I Ugwoke; M Armand; R Kinget; N Verbeke
Journal:  Respir Res       Date:  2001-04-12

Review 9.  Insulin and the lung: connecting asthma and metabolic syndrome.

Authors:  Suchita Singh; Y S Prakash; Allan Linneberg; Anurag Agrawal
Journal:  J Allergy (Cairo)       Date:  2013-09-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.